Steven Branston

Steven Branston has a diverse work experience in the biotechnology and pharmaceutical industries. Steven started their career as a Post-Doctoral Research Associate at University College London, where they focused on generating new E. coli strains for more efficient protein manufacturing. Steven then joined IMS Health as a Consulting Analyst before transitioning to a Post-Doctoral Researcher role at University College London, collaborating with NeuroPhage Pharmaceuticals on the purification of filamentous bacteriophage M13.

Steven then moved into the pharmaceutical industry, joining AmpliPhi Biosciences as a Scientist. In this role, they led the development of an R&D SOP portfolio for the production of bacteriophages and contributed to the development of a new production scheme for clinical trials. Steven later advanced to the position of Senior Scientist, where they established a dedicated product development team and developed PCR and potency assays for manufacturing.

Currently, Steven is working at Armata Pharmaceuticals as the Australia Site Head. Steven is responsible for overseeing activities at the company's Sydney site, including new product isolation, assay design, and process development. Steven plays a crucial role in the development of targeted bacteriophage therapeutics for antibiotic-resistant bacterial infections.

Steven Branston completed their education in a chronological order. Steven obtained their Bachelor of Arts and Master of Engineering degree in Chemical Engineering from the University of Cambridge, where they studied from 2000 to 2004. In 2001, they also received a scholarship for a one-year program in Chemical Engineering at the Massachusetts Institute of Technology. Later, from 2005 to 2009, Steven pursued their PhD in Biochemical Engineering at UCL (University College London).